Biomarkers in Predicting Response to Rituximab Treatment in Samples From Patients With Indolent Follicular Lymphoma

Sponsor
ECOG-ACRIN Cancer Research Group
Study ID
NCT01381705
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

  • rituximab — BIOLOGICAL
  • DNA analysis — GENETIC
  • gene expression analysis — GENETIC
  • polymorphism analysis — GENETIC
  • laboratory biomarker analysis — OTHER
  • medical chart review — OTHER

Study Details

RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients will respond to treatment. PURPOSE: This research study is studying biomarkers in predicting response to rituximab treatment in samples from patients with indolent follicular lymphoma.

Key Dates

Start date
Feb 6, 2012
Status verified
May 2017
Primary completion
Jul 6, 2012
Completion
Jul 6, 2012

Study Design

Enrollment
259 participants (actual)

Primary Outcome Measure

Correlation of FCGR3A 158V/F polymorphisms with response, duration of response, and time to rituximab resistance [ Time Frame: 1 year ]

Related Studies